These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15111537)

  • 1. Natural progression of diabetic peripheral neuropathy in the Zenarestat study population.
    Brown MJ; Bird SJ; Watling S; Kaleta H; Hayes L; Eckert S; Foyt HL;
    Diabetes Care; 2004 May; 27(5):1153-9. PubMed ID: 15111537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration.
    Nicolucci A; Carinci F; Cavaliere D; Scorpiglione N; Belfiglio M; Labbrozzi D; Mari E; Benedetti MM; Tognoni G; Liberati A
    Diabet Med; 1996 Dec; 13(12):1017-26. PubMed ID: 8973882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of repeated measures of nerve conduction and quantitative sensory testing in a diabetic neuropathy trial.
    Bird SJ; Brown MJ; Spino C; Watling S; Foyt HL
    Muscle Nerve; 2006 Aug; 34(2):214-24. PubMed ID: 16708368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy.
    Ziegler D; Mayer P; Rathmann W; Gries FA
    Diabetes Res Clin Pract; 1991 Oct; 14(1):63-73. PubMed ID: 1748064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan.
    Hotta N; Sakamoto N; Shigeta Y; Kikkawa R; Goto Y
    J Diabetes Complications; 1996; 10(3):168-72. PubMed ID: 8807467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.
    Bril V; Buchanan RA
    Diabetes Care; 2006 Jan; 29(1):68-72. PubMed ID: 16373898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reproducibility of parameters for assessment of diabetic neuropathy. The French Group for Research and Study of Diabetic Neuropathy.
    Valensi P; Attali JR; Gagant S
    Diabet Med; 1993 Dec; 10(10):933-9. PubMed ID: 8306589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranirestat for the management of diabetic sensorimotor polyneuropathy.
    Bril V; Hirose T; Tomioka S; Buchanan R;
    Diabetes Care; 2009 Jul; 32(7):1256-60. PubMed ID: 19366965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group.
    Santiago JV; Snksen PH; Boulton AJ; Macleod A; Beg M; Bochenek W; Graepel GJ; Gonen B
    J Diabetes Complications; 1993; 7(3):170-8. PubMed ID: 8343611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of vibratory quantitative sensory testing and nerve conduction studies in patients with diabetes.
    Kincaid JC; Price KL; Jimenez MC; Skljarevski V
    Muscle Nerve; 2007 Dec; 36(6):821-7. PubMed ID: 17683081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of treatment with an aldose-reductase inhibitor on symptomatic carpal tunnel syndrome in type 2 diabetes.
    Monge L; De Mattei M; Dani F; Sciarretta A; Carta Q
    Diabet Med; 1995 Dec; 12(12):1097-101. PubMed ID: 8750220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group.
    Greene DA; Arezzo JC; Brown MB
    Neurology; 1999 Aug; 53(3):580-91. PubMed ID: 10449124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.
    Nakayama M; Nakamura J; Hamada Y; Chaya S; Mizubayashi R; Yasuda Y; Kamiya H; Koh N; Hotta N
    Diabetes Care; 2001 Jun; 24(6):1093-8. PubMed ID: 11375376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The electrophysiological findings of subclinical neuropathy in patients with recently diagnosed type 1 diabetes mellitus.
    Karsidag S; Morali S; Sargin M; Salman S; Karsidag K; Us O
    Diabetes Res Clin Pract; 2005 Mar; 67(3):211-9. PubMed ID: 15713353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superficial radial sensory nerve potentials in immune-mediated and diabetic neuropathies.
    Tamura N; Kuwabara S; Misawa S; Mori M; Nakata M; Hattori T
    Clin Neurophysiol; 2005 Oct; 116(10):2330-3. PubMed ID: 16122982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of zenarestat, an aldose reductase inhibitor, on peripheral neuropathy in Zucker diabetic fatty rats.
    Shimoshige Y; Ikuma K; Yamamoto T; Takakura S; Kawamura I; Seki J; Mutoh S; Goto T
    Metabolism; 2000 Nov; 49(11):1395-9. PubMed ID: 11092500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between sural nerve morphometric findings and measures of peripheral nerve function in mild diabetic neuropathy.
    Veves A; Malik RA; Lye RH; Masson EA; Sharma AK; Schady W; Boulton AJ
    Diabet Med; 1991 Dec; 8(10):917-21. PubMed ID: 1838042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is ACE inhibition with lisinopril helpful in diabetic neuropathy?
    Reja A; Tesfaye S; Harris ND; Ward JD
    Diabet Med; 1995 Apr; 12(4):307-9. PubMed ID: 7600744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.
    Hotta N; Toyota T; Matsuoka K; Shigeta Y; Kikkawa R; Kaneko T; Takahashi A; Sugimura K; Koike Y; Ishii J; Sakamoto N;
    Diabetes Care; 2001 Oct; 24(10):1776-82. PubMed ID: 11574441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycemic control is related to the electrophysiologic severity of diabetic peripheral sensorimotor polyneuropathy.
    Tkac I; Bril V
    Diabetes Care; 1998 Oct; 21(10):1749-52. PubMed ID: 9773742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.